Home Applications 213217 Application 213217
Type NDA
Sponsor BEIGENE Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 BRUKINSA ZANUBRUTINIB CAPSULE;ORAL 80MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213217-001 BRUKINSA ZANUBRUTINIB 80MG CAPSULE / ORAL RLD 2019-11-14
Orange Book patents# Current patent rows page 1 of 1 · 68 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N213217-001 10570139 2034-04-22 U-1745 2021-06-04 N213217-001 10570139 2034-04-22 U-2145 2021-06-04 N213217-001 10570139 2034-04-22 U-2537 2021-06-04 N213217-001 10570139 2034-04-22 U-2666 2021-06-04 N213217-001 10570139 2034-04-22 U-3063 2021-06-04 N213217-001 10570139 2034-04-22 U-3486 2021-06-04 N213217-001 10570139 2034-04-22 U-3860 2021-06-04 N213217-001 11142528 2034-04-22 U-1745 Drug product 2021-11-12 N213217-001 11142528 2034-04-22 U-2145 Drug product 2021-11-12 N213217-001 11142528 2034-04-22 U-2537 Drug product 2021-11-12 N213217-001 11142528 2034-04-22 U-2666 Drug product 2021-11-12 N213217-001 11142528 2034-04-22 U-3063 Drug product 2021-11-12 N213217-001 11142528 2034-04-22 U-3486 Drug product 2021-11-12 N213217-001 11142528 2034-04-22 U-3860 Drug product 2021-11-12 N213217-001 9447106 2034-04-22 U-1745 Drug substance, Drug product 2019-11-20 N213217-001 9447106 2034-04-22 U-2145 Drug substance, Drug product 2019-11-20 N213217-001 9447106 2034-04-22 U-2537 Drug substance, Drug product 2019-11-20 N213217-001 9447106 2034-04-22 U-2666 Drug substance, Drug product 2019-11-20 N213217-001 9447106 2034-04-22 U-3063 Drug substance, Drug product 2019-11-20 N213217-001 9447106 2034-04-22 U-3486 Drug substance, Drug product 2019-11-20 N213217-001 9447106 2034-04-22 U-3860 Drug substance, Drug product 2019-11-20 N213217-001 10927117 2037-08-15 Drug substance, Drug product 2021-04-20 N213217-001 11591340 2037-08-15 U-1745 2023-03-08 N213217-001 11591340 2037-08-15 U-2145 2023-03-08 N213217-001 11591340 2037-08-15 U-2537 2023-03-08 N213217-001 11591340 2037-08-15 U-2666 2023-03-08 N213217-001 11591340 2037-08-15 U-3063 2023-03-08 N213217-001 11591340 2037-08-15 U-3486 2023-03-08 N213217-001 11591340 2037-08-15 U-3727 2023-03-08 N213217-001 11591340 2037-08-15 U-3728 2023-03-08 N213217-001 11591340 2037-08-15 U-3729 2023-03-08 N213217-001 11851437 2037-08-15 Drug substance, Drug product 2024-01-23 N213217-001 11884674 2037-08-15 U-1745 2024-02-28 N213217-001 11884674 2037-08-15 U-2145 2024-02-28 N213217-001 11884674 2037-08-15 U-2537 2024-02-28 N213217-001 11884674 2037-08-15 U-2666 2024-02-28 N213217-001 11884674 2037-08-15 U-3063 2024-02-28 N213217-001 11884674 2037-08-15 U-3486 2024-02-28 N213217-001 11884674 2037-08-15 U-3860 2024-02-28 N213217-001 11970500 2037-08-15 U-1745 2024-05-09 N213217-001 11970500 2037-08-15 U-2145 2024-05-09 N213217-001 11970500 2037-08-15 U-2537 2024-05-09 N213217-001 11970500 2037-08-15 U-2666 2024-05-09 N213217-001 11970500 2037-08-15 U-3063 2024-05-09 N213217-001 11970500 2037-08-15 U-3486 2024-05-09 N213217-001 11970500 2037-08-15 U-3860 2024-05-09 N213217-001 11701357 2039-06-24 U-3860 2024-04-02 N213217-001 11786531 2043-01-19 U-3715 2023-11-02 N213217-001 11786531 2043-01-19 U-3716 2023-11-02 N213217-001 11786531 2043-01-19 U-3717 2023-11-02 N213217-001 11786531 2043-01-19 U-3718 2023-11-02 N213217-001 11786531 2043-01-19 U-3719 2023-11-02 N213217-001 11786531 2043-01-19 U-3720 2023-11-02 N213217-001 11786531 2043-01-19 U-3875 2023-11-02 N213217-001 11896596 2043-01-19 U-3715 2024-03-12 N213217-001 11896596 2043-01-19 U-3716 2024-03-12 N213217-001 11896596 2043-01-19 U-3717 2024-03-12 N213217-001 11896596 2043-01-19 U-3718 2024-03-12 N213217-001 11896596 2043-01-19 U-3719 2024-03-12 N213217-001 11896596 2043-01-19 U-3720 2024-03-12 N213217-001 11896596 2043-01-19 U-3875 2024-03-12 N213217-001 11911386 2043-01-19 U-3715 2024-02-28 N213217-001 11911386 2043-01-19 U-3716 2024-02-28 N213217-001 11911386 2043-01-19 U-3717 2024-02-28 N213217-001 11911386 2043-01-19 U-3718 2024-02-28 N213217-001 11911386 2043-01-19 U-3719 2024-02-28 N213217-001 11911386 2043-01-19 U-3720 2024-02-28 N213217-001 11911386 2043-01-19 U-3875 2024-02-28
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 7 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 42 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N213217-001 BRUKINSA 80MG CAPSULE / ORAL RLD, RS 2019-11-14 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213217-001 BRUKINSA 80MG CAPSULE / ORAL RLD 2019-11-14 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 41 · 1,628 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N213217-001 10570139 2034-04-22 U-1745 2021-06-04 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 10570139 2034-04-22 U-2666 2021-06-04 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 10570139 2034-04-22 U-2537 2021-06-04 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 10570139 2034-04-22 U-3860 2021-06-04 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 10570139 2034-04-22 U-3063 2021-06-04 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 10570139 2034-04-22 U-3486 2021-06-04 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 10570139 2034-04-22 U-2145 2021-06-04 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11142528 2034-04-22 U-2666 Drug product 2021-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11142528 2034-04-22 U-2537 Drug product 2021-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11142528 2034-04-22 U-1745 Drug product 2021-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11142528 2034-04-22 U-2145 Drug product 2021-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11142528 2034-04-22 U-3063 Drug product 2021-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11142528 2034-04-22 U-3860 Drug product 2021-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11142528 2034-04-22 U-3486 Drug product 2021-11-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 9447106 2034-04-22 U-2145 Drug substance, Drug product 2019-11-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 9447106 2034-04-22 U-1745 Drug substance, Drug product 2019-11-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 9447106 2034-04-22 U-3063 Drug substance, Drug product 2019-11-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 9447106 2034-04-22 U-2537 Drug substance, Drug product 2019-11-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 9447106 2034-04-22 U-2666 Drug substance, Drug product 2019-11-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 9447106 2034-04-22 U-3860 Drug substance, Drug product 2019-11-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 9447106 2034-04-22 U-3486 Drug substance, Drug product 2019-11-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 10927117 2037-08-15 Drug substance, Drug product 2021-04-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-1745 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-2145 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-2537 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-2666 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-3063 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-3486 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-3727 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-3729 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11591340 2037-08-15 U-3728 2023-03-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11851437 2037-08-15 Drug substance, Drug product 2024-01-23 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11884674 2037-08-15 U-1745 2024-02-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11884674 2037-08-15 U-2145 2024-02-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11884674 2037-08-15 U-2537 2024-02-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11884674 2037-08-15 U-2666 2024-02-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11884674 2037-08-15 U-3063 2024-02-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11884674 2037-08-15 U-3486 2024-02-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11884674 2037-08-15 U-3860 2024-02-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213217-001 11970500 2037-08-15 U-1745 2024-05-09 d4dbc9d85df4…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 8 · 291 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 6 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 72579-011 BRUKINSA zanubrutinib BEIGENE USA, INC. NDA Current 72579-011 BRUKINSA zanubrutinib BeiGene USA, Inc. NDA Current 72579-011 BRUKINSA zanubrutinib BEIGENE USA, INC. NDA Current 72579-011 BRUKINSA zanubrutinib BeiGene USA, Inc. NDA Current 72579-011 BRUKINSA zanubrutinib Beigene Usa, Inc. NDA Current 72579-011 BRUKINSA zanubrutinib Beigene Usa, Inc. NDA Current